Relapse clinical trials

Explore recruiting relapse clinical trials.

Recruiting relapse studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapse trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-label randomized study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Fecal Microbiota Transplantation in the prevention of complications after allogeneic hematopoietic stem cell transplantation for hematologic malignancy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II Clinical Trial to optimize the dose of an anti-NKG2A monoclonal antibody (humZ270 mAb, IPH2201) for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing haploidentical transplantation with post-transplantation cyclophosphamide.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Leflunomide in PMR; A multicenter randomized placebo controlled treatment study of Leflunomide in polymyalgia rheumatica

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Ponatinib for the management of minimal residual disease (MRD) and hematologic relapsein adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients.ALL2620

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapse trials by city

Relapse in Toronto Relapse in Vancouver Relapse in Montreal Relapse in Calgary Relapse in Edmonton Relapse in Ottawa Relapse in Winnipeg Relapse in Quebec City Relapse in Hamilton Relapse in Kitchener Relapse in London Relapse in Halifax Relapse in New York Relapse in Los Angeles Relapse in Chicago Relapse in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease